Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Hofheinz · SciRah

Researcher profile · Semantic Scholar

R. Hofheinz

Share profile

R. Hofheinz — researcher profile on SciRah

h-index: 4
Works: 26
Citations: 63

Most-cited papers

Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study
S. Stintzing, S. Klein-Scory, Ludwig Fischer von Weikersthal, Martin Fuchs +21 more
2025Journal of Clinical Oncology14 citations
Semantic Scholar
Letter to the editors of the Journal of Cancer Research and Clinical Oncology
H. Matthes, R. Hofheinz, Gil Bar-Sela, D. Galun +5 more
2019Journal of Cancer Research and Clinical Oncology12 citations Open access
Semantic Scholar
FIRE-4 (AIO KRK-0114): Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab.
Lena Weiss, V. Heinemann, Ludwig Fischer von Weikersthal, F. Kaiser +16 more
2025Journal of Clinical Oncology8 citations
Semantic Scholar
Patients with Advanced or Metastasised Non-Small-Cell Lung Cancer with Viscum album L. Therapy in Addition to PD-1/PD-L1 Blockade: A Real-World Data Study
F. Schad, A. Thronicke, R. Hofheinz, H. Matthes +1 more
2024Cancers7 citations Open access
Semantic Scholar
Disease-free survival (DFS) and time to recurrence (TTR) with circulating tumor (ct) DNA–based decision for adjuvant treatment in colon cancer stage II (CIRCULATE): An AIO (KRK-0217)/ABCSG trial.
Gunnar Folprecht, S. Stasik, J. Christmann, Lukas Weiss +16 more
2026Journal of Clinical Oncology3 citations
Semantic Scholar
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
James J. Harding, R. Hofheinz, E. Élez, Y. Kuboki +14 more
2026Cancer Research Communications3 citations Open access
Semantic Scholar
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial
S. Lorenzen, T. Goetze, P. Thuss-Patience, J. Riera-Knorrenschild +17 more
2026Nature Communications3 citations Open access
Semantic Scholar
Expert-guided approaches to complementary interventions for common side effects of cancer therapies: a practice-based perspective from integrative oncology centers in Baden-Württemberg, Germany
Marcela Winkler, T. Breitkreuz, J. Brust, S. Frenzel +16 more
2025Frontiers in Oncology3 citations Open access
Semantic Scholar
Geriatric assessment and the variance of treatment recommendations in geriatric patients with gastrointestinal cancer—a study in AIO oncologists
M. Büttelmann, R. Hofheinz, A. Kröcher, U. Ubbelohde +4 more
2023ESMO Open3 citations Open access
Semantic Scholar
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI
D. W. Mueller, S. Moenig, A. Vogel, S. Lorenzen +16 more
2017BMC Cancer3 citations Open access
Semantic Scholar
Tumor Response and Its Impact on Treatment Failure in Rectal Cancer: Does Intensity of Neoadjuvant Treatment Matter?
M. Diefenhardt, D. Martin, Maximilian Fleischmann, R. Hofheinz +3 more
2024Cancers2 citations Open access
Semantic Scholar
Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence
F. Schad, A. Thronicke, R. Hofheinz, R. Klein +4 more
2024Pharmaceuticals2 citations
Semantic Scholar
Preoperative Immunotherapy in Oncology.
R. Hofheinz, Sylvie Lorenzen, Martin Sebastian, S. Bölükbas +2 more
2026Deutsches Ärzteblatt International1 citations Open access
Semantic Scholar
Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF‐PARAGON study)
T. Goetze, S. Al-Batran, Ruediger Liersch, Lars Scheuer +15 more
2025International Journal of Cancer1 citations Open access
Semantic Scholar
Postoperative cfDNA levels and ctDNA detection rates in patients with stage II colon cancer screened for CIRCULATE (AIO-KRK-0217, ABCSG).
S. Stasik, Christian Thiede, Sarah Albus, E. Goekkurt +12 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
A randomized controlled clinical trial of intranasal versus subcutaneous midazolam for agitation in terminal illness (MinTU study)
H. Hirschinger, Constanze Rémi, Evelyn Jäger, S. Nittka +13 more
2026Palliative Medicine0 citations Open access
Semantic Scholar
Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial.
M. Masetti, A. Nieto, Sylvie Lorenzen, T. Goetze +21 more
2026European Journal of Cancer0 citations Open access
Semantic Scholar
Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629).
R. Hofheinz, L. V. von Weikersthal, T. Dechow, R. Depenbusch +14 more
2026European Journal of Cancer0 citations Open access
Semantic Scholar
Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial
S. Lorenzen, T. Goetze, P. Thuss-Patience, J. Riera-Knorrenschild +17 more
2026Nature Communications0 citations Open access
Semantic Scholar
FIRE-4 (AIO KRK-0114): Efficacy of third-line rechallenge with cetuximab versus investigator’s choice in relation to the interval between initial and third-line anti-EGFR therapy.
Lena Weiss, S. Stintzing, Ludwig Fischer von Weikersthal, F. Kaiser +16 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Hemodynamic effects of red blood cell transfusion in patients with hemato-oncologic diseases
B. Yazdani, N. Schneider, M. Abba, M. Schulz +6 more
2026Frontiers in Medicine0 citations Open access
Semantic Scholar
Abstract LB010: First-line (1L) trastuzumab deruxtecan (T-DXd) regimens in advanced HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Exploratory analysis of baseline HER2-related biomarkers in DESTINY-Gastric03 (DG-03) Par
Y. Janjigian, H. V. van Laarhoven, S. Rha, V. Kozlov +18 more
2026Cancer Research0 citations
Semantic Scholar
Predictors of Successful Whole-Body Hyperthermia in Cancer Patients: Target Temperature Achievement and Safety Analysis
A. Hohneck, Vivien Schmitz-Solheid, D. Gencer, Maik Schroeder +6 more
2025Cancers0 citations Open access
Semantic Scholar
PD-1/PD-L1 Blockade Combined with AbnobaViscum Therapy is Linked to Improved Survival in Advanced or Metastatic NSCLC Patients, an ESMO-GROW Related Re-al-World Data Registry Study
F. Schad, A. Thronicke, R. Hofheinz, R. Klein +4 more
2024medRxiv0 citations Open access
Semantic Scholar
1333P S1 Guideline for prioritisation in gastrointestinal cancer care: Scarcity of resources in the pandemic context
A. Reinacher-Schick, C. Lugnier, S. Sommerlatte, T. Birkner +15 more
2022Annals of Oncology0 citations Open access
Semantic Scholar
Locally advanced rectal cancer : Current and future perioperative treatment strategies
R. Hofheinz
20200 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Angermeier×6
Invite
S. Angermeier — researcher profile on SciRah
C. Pauligk×6
Invite
C. Pauligk — researcher profile on SciRah
M. Loose×5
Invite
M. Loose — researcher profile on SciRah
S. Al-Batran×5
Invite
S. Al-Batran — researcher profile on SciRah

×4

Invite

Martin Fuchs — researcher profile on SciRah

Invite

E. Goekkurt — researcher profile on SciRah

J. Riera-Knorrenschild×4

Invite

J. Riera-Knorrenschild — researcher profile on SciRah

A. Reinacher-Schick×4

Invite

A. Reinacher-Schick — researcher profile on SciRah

Invite

T. Goetze — researcher profile on SciRah

Invite

T. Ettrich — researcher profile on SciRah

Invite

D. Pink — researcher profile on SciRah

Ludwig Fischer von Weikersthal×3

Invite

Ludwig Fischer von Weikersthal — researcher profile on SciRah